Anika Therapeutics, Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $113.4M | $103.4M | $93.0M | $105.6M | $75.1M | $71.4M | $64.8M | $55.6M |
| Cost of Revenue | $27.4M | $24.0M | $21.1M | $20.9M | $22.8M | $29.0M | $26.8M | $23.8M |
| Gross Profit | $86.1M | $79.4M | $71.9M | $84.7M | $52.3M | $42.4M | $38.0M | $31.7M |
| Gross Margin | 75.9% | 76.8% | 77.4% | 80.2% | 69.7% | 59.4% | 58.7% | 57.1% |
| Operating Expenses | ||||||||
| Research & Development | $18.8M | $10.7M | $9.0M | $8.1M | $7.1M | $5.4M | $6.2M | $6.9M |
| SG&A Expense | $21.5M | $18.0M | $14.8M | $15.1M | $12.9M | $14.7M | $17.9M | $17.3M |
| Operating Income | $45.7M | $50.6M | $48.1M | $61.4M | $32.6M | $19.7M | $14.0M | $7.5M |
| Operating Margin | 40.3% | 49.0% | 51.8% | 58.2% | 43.4% | 27.6% | 21.6% | 13.6% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $46.2M | $50.9M | $48.3M | $61.5M | $32.5M | $19.5M | $13.8M | $7.3M |
| Income Tax Expense | $14.4M | $18.3M | $17.5M | $23.2M | $11.9M | $7.8M | $5.3M | $3.0M |
| Net Income | $31.8M | $32.5M | $30.8M | $38.3M | $20.6M | $11.8M | $8.5M | $4.3M |
| Net Margin | 28.1% | 31.5% | 33.1% | 36.3% | 27.4% | 16.5% | 13.1% | 7.8% |
| EPS (Basic) | $2.18 | $2.22 | $2.06 | $2.61 | $1.46 | $0.89 | $0.65 | $0.34 |
| EPS (Diluted) | $2.11 | $2.15 | $2.01 | $2.51 | $1.39 | $0.82 | $0.62 | $0.32 |
| Shares Outstanding (Basic) | 14.6M | 14.7M | 14.9M | 14.7M | 14.1M | 13.3M | 13.1M | 12.6M |
| Shares Outstanding (Diluted) | 15.1M | 15.1M | 15.3M | 15.3M | 14.8M | 14.3M | 13.7M | 13.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |